Industry-leading iPSC Gene Editing Technology
Get the highest precision and efficiency with Ncardia’s proprietary STAR-CRISPR technology
STAR-CRISPR far surpasses other established gene editing methodologies.
Partner with Ncardia to:
- Reduce unintended edits in oncogenes and coding regions
- Mitigate safety risks in iPSC genetic modifications
- Access knock-out efficiency of ~90%, surpassing Cas9 and MAD7
- Utilize knock-in efficiency up to 50%, 2-3 times higher than other methods
Power Your Research With STAR-CRISPR Technology
What to Expect From Ncardia iPSC Gene Editing Service
Unmatched Efficiency
and minimal off-targets
Streamlined Experience
With Ncardia's proprietary technology
Quick Turnaround
Get your iPSC line edited in 12-16 weeks
How Does STAR-CRISPR Measure Up?
CRISPR-based systems have two key components:
- Guide RNA (gRNA) — a short RNA sequence matching the target DNA sequence to be edited
- DNA cutting enzyme — typically Cas9 or their derivatives
Among all the CRISPR-based systems available to edit iPSCs, STAR-CRISPR stands out with:
Unparalleled efficiencies in gene knock-in and knock-out
Minimal off-target editing
STAR-CRISPR offers about a 90% of Knock-out efficiency, surpassing Cas9 and MAD7
Knock-in efficiency is 2–3 times higher than other leading CRISPR-based methods when applied to iPSCs
STAR-CRISPR significantly mitigates the risk of unintended edits, also called off-targets, when compared to Cas9 in iPSCs
Explore Related Services
Partner With the Proven iPSC Technology Experts
Are you ready to confidently advance your therapeutic candidates?
Start a Conversation